{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:27:12Z","timestamp":1794641232214,"version":"4.9.1"},"reference-count":60,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T00:00:00Z","timestamp":1657584000000},"content-version":"unspecified","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000008","name":"Health Canada","doi-asserted-by":"publisher","award":["1920-HQ-000031"],"award-info":[{"award-number":["1920-HQ-000031"]}],"id":[{"id":"10.13039\/501100000008","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,6,20]]},"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Pharmaceutical industry involvement in medical education, research and clinical practice can lead to conflicts of interest. Within this context, this study examined how the \u2018Suboxone Education Programme\u2019, developed and delivered by a pharmaceutical company as part of a federally regulated risk management program, was presented as a solution to various kinds of risks relating to opioid use in public documents from medical institutions across Canada.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>These documents were issued during the Canadian opioid crisis, a time when the involvement of industry in health policy was being widely questioned given industry\u2019s role in driving the overprescribing of opioid analgesics and contributing to population-level harms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A critical discourse analysis of 69 documents collected between July 2020 and May 2021 referencing the Suboxone Education Program spanning 13 years (2007\u20132021) from medical, nursing and pharmacy institutions sourced from every Canadian province and territory. Discursive themes were identified through iterative and duplicate analyses using a semistructured data extraction instrument.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Documents characterised the Programme as addressing iatrogenic risks from overprescribing opioid analgesics, environmental risks from a toxic street drug supply and pharmacological risks relating to the dominant therapeutic alternative of methadone. The programme was identified as being able to address these risks by providing mechanisms to surveil healthcare professionals and to facilitate the prescribing of Suboxone. Medical institutions legitimised the Suboxone Education Programme by lending their regulatory, epidemiological and professional authority.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Addressing risk is considered as a central, moral responsibility of contemporary healthcare services. In this case, moral imperatives to address opioid crisis-related risks overrode other ethical concerns regarding conflicts of interest between industry and public welfare. Failing to address these conflicts potentially imperils efforts of mitigating population health harms by propagating an important driving force of the opioid crisis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-059561","type":"journal-article","created":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T13:17:47Z","timestamp":1657631867000},"page":"e059561","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["How the Suboxone Education Programme presented as a solution to risks in the Canadian opioid crisis: a critical discourse analysis"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8354-6153","authenticated-orcid":false,"given":"Abhimanyu","family":"Sud","sequence":"first","affiliation":[{"name":"Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada"},{"name":"Bridgepoint Collaboratory for Research and Innovation, Sinai Health System, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Strang","sequence":"additional","affiliation":[{"name":"Department of Sociology, York University, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Z","family":"Buchman","sequence":"additional","affiliation":[{"name":"Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada"},{"name":"Bioethics Program, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheryl","family":"Spithoff","sequence":"additional","affiliation":[{"name":"Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Department of Family and Community Medicine, Women's College Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross E G","family":"Upshur","sequence":"additional","affiliation":[{"name":"Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Bridgepoint Collaboratory for Research and Innovation, Sinai Health System, Toronto, Ontario, Canada"},{"name":"Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Webster","sequence":"additional","affiliation":[{"name":"Arthur Labatt Family School of Nursing, Western University, London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7640-8614","authenticated-orcid":false,"given":"Quinn","family":"Grundy","sequence":"additional","affiliation":[{"name":"Lawrence S Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,7,12]]},"reference":[{"key":"2025121603021440000_12.7.e059561.1","unstructured":"Government of Canada . Joint statement of action to address the opioid crisis. Ottawa, ON: Government of Canada, 2016."},{"key":"2025121603021440000_12.7.e059561.2","unstructured":"Moving towards improved access for evidence-based opioid addiction care in British Columbia. recommendations from the British Columbia node of the Canadian research initiative on substance misuse. BC Centre for Excellence in HIV\/AIDS 2016."},{"key":"2025121603021440000_12.7.e059561.3","first-page":"281","article-title":"Buprenorphine: new treatment of opioid addiction in primary care","volume":"57","author":"Kahan","year":"2011","journal-title":"Can Fam Physician"},{"key":"2025121603021440000_12.7.e059561.4","unstructured":"Canadian Medical Association . Guidelines for physicians in interactions with industry. Ottawa, ON: Canadian Medical Association, 2007."},{"key":"2025121603021440000_12.7.e059561.5","unstructured":"Royal College of Physicians and Surgeons of Canada, The College of Family Physicians of Canada, College des Medecins du Quebec . National standard for support of accredited CPD activities, 2018."},{"key":"2025121603021440000_12.7.e059561.6","unstructured":"Indivior UK Limited . Suboxone (buprenorphine and naloxone) product monograph. Indivior UK Limited, 2007."},{"key":"2025121603021440000_12.7.e059561.7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/jamainternmed.2019.5459","article-title":"Evaluation of the Extended-Release\/Long-Acting opioid prescribing risk evaluation and mitigation strategy program by the US food and drug administration: a review","volume":"180","author":"Heyward","year":"2020","journal-title":"JAMA Intern Med"},{"key":"2025121603021440000_12.7.e059561.8","unstructured":"Lurie J . Doctors Receive Opioid Training. Big Pharma Funds It. What Could Go Wrong? Mother Jones [Internet]. Available: http:\/\/www.motherjones.com\/politics\/2018\/04\/doctors-are-required-to-receive-opioid-training-big-pharma-funds-it-what-could-go-wrong\/ [Accessed 1 Sep 2021]."},{"key":"2025121603021440000_12.7.e059561.9","unstructured":"Health Canada . Submission of targeted risk management plans and follow-up commitments for prescription Opioid-Containing products: guidance for industry. Health Canada, 2018: 29."},{"key":"2025121603021440000_12.7.e059561.10","unstructured":"Recommendation M . National consultation on the Sectionsection 56 exemption requirement for methadone prescribing. CRISM, 2017."},{"key":"2025121603021440000_12.7.e059561.11","unstructured":"Strang J . Drug misuse and dependence: UK guidelines on clinical management, 2017. Available: https:\/\/researchportal.bath.ac.uk\/en\/publications\/drug-misuse-and-dependence-uk-guidelines-on-clinical-management"},{"key":"2025121603021440000_12.7.e059561.12","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1465-3362.2010.00212.x","article-title":"Methadone and buprenorphine prescribing patterns of Victorian general practitioners: their first 5 years after authorisation","volume":"30","author":"Longman","year":"2011","journal-title":"Drug Alcohol Rev"},{"key":"2025121603021440000_12.7.e059561.13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/jamapsychiatry.2018.3685","article-title":"Buprenorphine deregulation and Mainstreaming treatment for opioid use disorder: X the X Waiver","volume":"76","author":"Fiscella","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"2025121603021440000_12.7.e059561.14","doi-asserted-by":"crossref","unstructured":"Fraser S , Valentine K . Substance and substitution: methadone subjects in liberal societies. Springer, 2008: 203.","DOI":"10.1057\/9780230582569"},{"key":"2025121603021440000_12.7.e059561.15","doi-asserted-by":"publisher","DOI":"10.1177\/0306312708101047"},{"key":"2025121603021440000_12.7.e059561.16","doi-asserted-by":"publisher","DOI":"10.1007\/s11013-009-9129-3"},{"key":"2025121603021440000_12.7.e059561.17","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-145-4-200608150-00008"},{"key":"2025121603021440000_12.7.e059561.18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1273"},{"key":"2025121603021440000_12.7.e059561.19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0248238","article-title":"A comparison of educational events for physicians and nurses in Australia sponsored by opioid manufacturers","volume":"16","author":"Grundy","year":"2021","journal-title":"PLoS One"},{"key":"2025121603021440000_12.7.e059561.20","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/ACM.0000000000004186","article-title":"Evaluations of continuing health provider education focused on opioid prescribing: a scoping review","volume":"97","author":"Sud","year":"2022","journal-title":"Acad Med"},{"key":"2025121603021440000_12.7.e059561.21","first-page":"161","article-title":"MEDIA(TED) DISCOURSE AND SOCIETY","volume":"9","author":"Carvalho","year":"2008","journal-title":"Journal Stud"},{"key":"2025121603021440000_12.7.e059561.22","first-page":"45","article-title":"Policy as discourse: what does it mean? where does it get us?","volume":"21","author":"Bacchi","year":"2000","journal-title":"Disco: Stud in the Cultu Polit Educa"},{"key":"2025121603021440000_12.7.e059561.23","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-001574","article-title":"The organising vision for telehealth and telecare: discourse analysis","volume":"2","author":"Greenhalgh","year":"2012","journal-title":"BMJ Open"},{"key":"2025121603021440000_12.7.e059561.24","doi-asserted-by":"publisher","DOI":"10.1093\/fampra\/cmp038"},{"key":"2025121603021440000_12.7.e059561.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2018.03.015"},{"key":"2025121603021440000_12.7.e059561.26","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/medu.12429","article-title":"Compassionate care? A critical discourse analysis of accreditation standards","volume":"48","author":"Whitehead","year":"2014","journal-title":"Med Educ"},{"key":"2025121603021440000_12.7.e059561.27","doi-asserted-by":"crossref","first-page":"112642","DOI":"10.1016\/j.socscimed.2019.112642","article-title":"A critical content analysis of media reporting on opioids: the social construction of an epidemic","volume":"244","author":"Webster","year":"2020","journal-title":"Soc Sci Med"},{"key":"2025121603021440000_12.7.e059561.28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1550"},{"key":"2025121603021440000_12.7.e059561.29","doi-asserted-by":"crossref","unstructured":"Arribas-Ayllon M , Walkerdine V . Chapter 6 | Foucauldian Discourse Analysis. In: The SAGE Handbook of qualitative research in psychology. Sage, 2008: 91\u2013108.doi:10.4135\/9781848607927.n6","DOI":"10.4135\/9781848607927.n6"},{"key":"2025121603021440000_12.7.e059561.30","unstructured":"Indivior PLC . Terms and Conditions of Use of Web Site [Internet]. Suboxone Training Program. Available: https:\/\/www.suboxonetrainingprogram.ca\/ [Accessed 10 Mar 200]."},{"key":"2025121603021440000_12.7.e059561.31","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-040541"},{"key":"2025121603021440000_12.7.e059561.32","unstructured":"Beck U , Lash S , Wynne B . Risk society: towards a new modernity. SAGE Publications, 1992: 260."},{"key":"2025121603021440000_12.7.e059561.33","unstructured":"Alberta College of Pharmacy . Medication-Assisted treatment for opioid dependence: guidelines for pharmacists and pharmacy technicians. Alberta College of Pharmacy, 2014."},{"key":"2025121603021440000_12.7.e059561.34","unstructured":"Freidson E . Profession of medicine: a study of the sociology of applied knowledge. University of Chicago Press, 1988: 419."},{"key":"2025121603021440000_12.7.e059561.35","unstructured":"Indivior PLC . Privacy Policy of Web Site [Internet]. Privacy Policy - Suboxone Training Program. Available: www.suboxonetrainingprogram.ca [Accessed 10 Mar 2020]."},{"key":"2025121603021440000_12.7.e059561.36","unstructured":"Brissette S . La bupr\u00e9norphine dans Le traitement de la d\u00e9pendance aux opio\u00efdes: lignes directrices. Coll\u00e8ge des m\u00e9decins du Qu\u00e9bec, 2009: 45."},{"key":"2025121603021440000_12.7.e059561.37","doi-asserted-by":"publisher","DOI":"10.1136\/medethics-2013-101343"},{"key":"2025121603021440000_12.7.e059561.38","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2007.131714"},{"key":"2025121603021440000_12.7.e059561.39","doi-asserted-by":"crossref","first-page":"24S","DOI":"10.1177\/0033354918793627","article-title":"A public health strategy for the opioid crisis","volume":"133","author":"Saloner","year":"2018","journal-title":"Public Health Rep"},{"key":"2025121603021440000_12.7.e059561.40","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMp1906680","article-title":"Abuses of FDA Regulatory Procedures - The Case of Suboxone","volume":"382","author":"Haffajee","year":"2020","journal-title":"N Engl J Med"},{"key":"2025121603021440000_12.7.e059561.41","doi-asserted-by":"publisher","DOI":"10.3233\/JRS-170731"},{"key":"2025121603021440000_12.7.e059561.42","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.bjsw.a011317"},{"key":"2025121603021440000_12.7.e059561.43","unstructured":"SAGE Books - The New Public Health: Health and Self in the Age of Risk. Available: http:\/\/sk.sagepub.com\/books\/the-new-public-health\/n1.xml [Accessed 1 Sep 2021]."},{"key":"2025121603021440000_12.7.e059561.44","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1080\/0308514032000176720","article-title":"Technics over life: risk, ethics and the existential condition in high-tech antenatal care","volume":"33","author":"Hel\u00e9n","year":"2004","journal-title":"Econ Soc"},{"key":"2025121603021440000_12.7.e059561.45","unstructured":"Beck U , Wynne B . Risk society: towards a new modernity. SAGE, 1992: 260."},{"key":"2025121603021440000_12.7.e059561.46","unstructured":"Timmermans S , Berg M . The gold standard: the challenge of evidence-based medicine. Temple University Press, 2010."},{"key":"2025121603021440000_12.7.e059561.47","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/0277-9536(94)00150-R","article-title":"Psychosocial theory and the creation of the risky self","volume":"40","author":"Ogden","year":"1995","journal-title":"Soc Sci Med"},{"key":"2025121603021440000_12.7.e059561.48","unstructured":"JJ L . Blockbuster drugs. Oxford University Press, 2014."},{"key":"2025121603021440000_12.7.e059561.49","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m2983"},{"key":"2025121603021440000_12.7.e059561.50","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/jlme.12068","article-title":"Institutional corruption of pharmaceuticals and the myth of safe and effective drugs","volume":"41","author":"Light","year":"2013","journal-title":"J Law Med Ethics"},{"key":"2025121603021440000_12.7.e059561.51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000335"},{"key":"2025121603021440000_12.7.e059561.52","unstructured":"Lobbyists Registration . Office of the integrity commissioner. Available: http:\/\/www.oico.on.ca\/home\/lobbyists-registration\/overview [Accessed 19 Nov 2019]."},{"key":"2025121603021440000_12.7.e059561.53","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/1073110520935340","article-title":"The public health value of opioid litigation","volume":"48","author":"Haffajee","year":"2020","journal-title":"J Law Med Ethics"},{"key":"2025121603021440000_12.7.e059561.54","doi-asserted-by":"crossref","first-page":"103556","DOI":"10.1016\/j.drugpo.2021.103556","article-title":"Mal\/adaptations: a qualitative evidence synthesis of opioid agonist therapy during major disruptions","volume":"101","author":"Salamanca-Buentello","year":"2022","journal-title":"Int J Drug Policy"},{"key":"2025121603021440000_12.7.e059561.55","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jamainternmed.2018.6721","article-title":"Assessment of racial\/ethnic and income disparities in the prescription of opioids and other controlled medications in California","volume":"179","author":"Friedman","year":"2019","journal-title":"JAMA Intern Med"},{"key":"2025121603021440000_12.7.e059561.56","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jamapsychiatry.2022.0004","article-title":"Evaluation of increases in drug overdose mortality rates in the US by race and ethnicity before and during the COVID-19 pandemic","volume":"79","author":"Friedman","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"2025121603021440000_12.7.e059561.57","unstructured":"Reuter N . Saving lives with a single shot: strategies and challenges to expanded naloxone availability. in Indivior, PLC. Available: https:\/\/apha.confex.com\/apha\/144am\/meetingapi.cgi\/Session\/48653?filename=144am_Session48653.html & template=Word"},{"key":"2025121603021440000_12.7.e059561.58","unstructured":"Indivior Calls for Widespread Commitment to Tackling Stigma in Patients with Opioid Use Disorder [Internet]. Indivior Press Releases, 2020. Available: https:\/\/www.indivior.com\/en\/media\/press-releases\/indivior-calls-for-widespread-commitment-to-tackling-stigma-in-patients-with-opiod-use-disorder [Accessed 10 May 2022]."},{"key":"2025121603021440000_12.7.e059561.59","first-page":"5","article-title":"Indivior\u2010sponsored event focuses on opioids during COVID\u201019","volume":"33","author":"Knopf","year":"2021","journal-title":"Alcohol Drug Abuse Wkly"},{"key":"2025121603021440000_12.7.e059561.60","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/add.13067","article-title":"Should academic journals publish e-cigarette research linked to tobacco companies?","volume":"111","author":"Shaw","year":"2016","journal-title":"Addiction"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-059561","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T11:02:31Z","timestamp":1765882951000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-059561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":60,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7,12]]},"published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1136\/bmjopen-2021-059561"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-059561","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bmjopen-2021-059561.supp1","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bmjopen-2021-059561.supp2","asserted-by":"subject"}]},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}